S
Saby George
Researcher at Roswell Park Cancer Institute
Publications - 167
Citations - 14398
Saby George is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Nivolumab & Renal cell carcinoma. The author has an hindex of 31, co-authored 138 publications receiving 10182 citations. Previous affiliations of Saby George include Memorial Sloan Kettering Cancer Center & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
RANK Ligand: Effects of Inhibition
TL;DR: Denosumab is a fully human monoclonal antibody against RANKL, which has been demonstrated in large, randomized, phase 3 studies to be effective in preventing fractures and bone loss, and improving the bone mineral density in various cancerous and noncancerous settings.
Journal ArticleDOI
Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
Andrea B. Apolo,Thomas Powles,Mauricio Burotto,Maria T Bourlon,James J. Hsieh,Umberto Basso,Amishi Yogesh Shah,Cristina Suárez,Camillo Porta,Carlos H. Barrios,Howard Gurney,Elizabeth R. Kessler,Margitta Retz,Saby George,Bernard Escudier,Joshua Zhang,Burcin Simsek,Christian Scheffold,Robert J. Motzer,Toni K. Choueiri +19 more
TL;DR: E efficacy benefits with N+C vs S were observed regardless of IMDC risk status, organ site of mets, or extent of tumor burden at baseline, and these results support N-C as a new first-line treatment option for pts with aRCC.
Journal ArticleDOI
Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
David F. McDermott,Brian I. Rini,Robert J. Motzer,Nizar M. Tannir,Bernard Escudier,Christian Kollmannsberger,Hans J. Hammers,C. Porta,Saby George,Frede Donskov,Howard Gurney,M.-O. Grimm,Michael R. Harrison,Thomas E. Hutson,Justin Doan,Shuo Yang,Sumati Rao,Sabeen Mekan,A. Ambavane,Thomas Powles +19 more
TL;DR: This research presents a novel and scalable approach to modeling and simulation that allows for real-time decision-making in the design and execution of individualized treatment plans for cancer patients.
Journal ArticleDOI
Incidence of Clear Cell Papillary Renal Cell Carcinoma in Low-Grade Renal Cell Carcinoma Cases A 12-Year Retrospective Clinicopathologic Study From a Single Cancer Center
TL;DR: CCPRCC is not uncommon among small low-grade RCC tumors and can be correctly recognized by its unique histomorphological features and confirmed by immunohistochemistry studies, which is important due to the excellent clinical outcome following resection.
Journal ArticleDOI
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
TL;DR: An overview of different therapeutic options available as second-line treatment in patients with mRCC along with future directions is provided.